Search research articles
Contact Us
Filters
Showing results (291-300 of 295) with videos related to
Page
of 30
Sort By:
You have reached the last page of results.
This site can display upto 295 results.
Light, Science & Applications
|
February 2, 2026
Polarization-sensitive neuromorphic vision sensing enabled by pristine black arsenic-phosphorus
Shi Zhang, Shuguang Zhu, Shijian Tian, et al.
Nature Communications
|
February 2, 2023
Tautomerism unveils a self-inhibition mechanism of crystallization
Weiwei Tang, Taimin Yang, Cristian A Morales-Rivera, et al.
Cell Death Discovery
|
August 17, 2021
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer
Weiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M A Pillai, et al.
Communications Biology
|
October 30, 2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
Mengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2022
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, et al.
Page
of 30
Search research articles
Search
Showing results (291-300 of 295) with videos related to
Sort By:
Page
of 30
You have reached the last page of results.
This site can display upto 295 results.
Light, Science & Applications
|
February 2, 2026
Polarization-sensitive neuromorphic vision sensing enabled by pristine black arsenic-phosphorus
Shi Zhang, Shuguang Zhu, Shijian Tian, et al.
Nature Communications
|
February 2, 2023
Tautomerism unveils a self-inhibition mechanism of crystallization
Weiwei Tang, Taimin Yang, Cristian A Morales-Rivera, et al.
Cell Death Discovery
|
August 17, 2021
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer
Weiwei Tang, Kumaraguruparan Ramasamy, Sureshkumar M A Pillai, et al.
Communications Biology
|
October 30, 2021
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
Mengxing Li, Suryavathi Viswanadhapalli, Bindu Santhamma, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2022
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, et al.
Page
of 30